Company / Board of Directors /

CEO


Lottin Christophe

Christophe Lottin, who has twenty years of experience in cardiology, rose through the sales organization of Boston Scientific and Hexacath France, up to the position of President with responsibility for Benelux, Switzerland and Canada. In particular, he was instrumental in the commercial success of the Optimax coronary stent. In his multiple roles, he had to coordinate the critical departments of a stent company, such as R&D, Clinical and Regulatory affairs.
Christophe was appointed CEO of STENTYS in summer 2016.

 
Updated 2017-04-03